EFFECT filed Aug 26, 2026 at 00:15 ET
The SEC declared effective Indaptus Therapeutics' S-3 registration (File No. 333-298388) on August 25, 2026, covering up to 58,895,000 shares of common stock for resale by selling stockholders. This effectiveness, combined with a prior S-3 from June 2026 covering 18,864,000 shares, creates a massive potential overhang of up to ~77.8 million shares (~58% of outstanding) that selling stockholders can now sell into the market at any time. The company has no active clinical programs, having discontinued its lead candidate Decoy20, and is evaluating strategic alternatives, making this a significant bearish catalyst for the stock.